期刊文献+

Highlights on FOXO3 and tumor-associated dendritic :ells in prostate cancer 被引量:1

Highlights on FOXO3 and tumor-associated dendritic :ells in prostate cancer
下载PDF
导出
摘要 Cancer immunotherapy sometimes fails to provoke effective immune responsesbecause of immunosuppressive mechanisms present in the tumor-bearing host. Dendritic cells (DCs) are the most potent antigenpresenting cells. After internalizing tumorassociated antigens (TAAs) at the tumor site, Cancer immunotherapy sometimes fails to provoke effective immune responsesbecause of immunosuppressive mechanisms present in the tumor-bearing host. Dendritic cells (DCs) are the most potent antigenpresenting cells. After internalizing tumorassociated antigens (TAAs) at the tumor site,
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2011年第5期657-658,共2页 亚洲男性学杂志(英文版)
  • 相关文献

参考文献10

  • 1Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE et al. FOX03 programs tumorassociated DCs to become tolerogenic in human and murine prostate cancer, J Clin Invest 2011; 121: 1361-72.
  • 2Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 1-24.
  • 3Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A et aL Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Eng J Med 2004: 351: 1502-12.
  • 4Arlen PM, Mohebtash M, Madan RA, Gulley JL. Promising novel immunotherapies and combinations for prostate cancer. Future Oncol2009; 5: 187-96.
  • 5Kantoff P, Higano C, Shore N, Berger E, Small E etaL SipuleuceI-T immunotherapy for castration-resistant prostate cancer. N Eng J Med 2010; 363:411-22.
  • 6Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M et al. CD4^+CD25^high T cells are enriched in tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177: 7398-405.
  • 7Yokokawa J, Cereda V, Remondo C, Gulley J L, Aden PM et al. En hanced functionality of CD4^+CD25^high FoxP3^+regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008; 14: 1032-40.
  • 8Barnett B, Kryczek I, Cheng P, Zou W. Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005; 54: 369-77.
  • 9Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59: 663-74.
  • 10Vergati M, Cereda V, Madan RV, Gulley JL, Huen NY et al. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer preversus post-vaccination. Cancer Immunol Immunother 2011; 60: 197-206.

同被引文献1

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部